NovaBridge Biosciences Asset Resilience Ratio
NovaBridge Biosciences asset resilience ratio. NovaBridge Biosciences (NBP) has an Asset Resilience Ratio of 0.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NovaBridge Biosciences (NBP) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NovaBridge Biosciences (2017–2025)
Asset resilience ratio of NovaBridge Biosciences from 2017 to 2025. This chart shows how NovaBridge Biosciences's Asset Resilience Ratio has changed over time. Read total liabilities of NovaBridge Biosciences for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NovaBridge Biosciences's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NovaBridge Biosciences (NBP) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $210.00K | 0.09% |
| Total Liquid Assets | $210.00K | 0.09% |
Asset Resilience Insights
- Limited Liquidity: NovaBridge Biosciences maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NovaBridge Biosciences Industry Peers by Asset Resilience Ratio
Compare NovaBridge Biosciences's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
NovaBridge Biosciences Asset Resilience Ratio by Year (2017–2025)
NovaBridge Biosciences asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for NovaBridge Biosciences.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.08% | $30.02K | $37.24 Million | -49.35pp |
| 2024-12-31 | 49.43% | $767.36 Million | $1.55 Billion | +43.95pp |
| 2023-12-31 | 5.48% | $20.22 Million | $368.92 Million | -0.30pp |
| 2022-12-31 | 5.78% | $235.43 Million | $4.07 Billion | -7.67pp |
| 2021-12-31 | 13.45% | $118.16 Million | $878.74 Million | +12.95pp |
| 2020-12-31 | 0.50% | $31.53 Million | $6.33 Billion | -1.34pp |
| 2019-12-31 | 1.84% | $32.00 Million | $1.74 Billion | -8.93pp |
| 2018-12-31 | 10.77% | $255.96 Million | $2.38 Billion | -15.19pp |
| 2017-12-31 | 25.97% | $266.25 Million | $1.03 Billion | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy… Read more